Sign In
Buy ADAP
$0.0549
+0 (+0%)
At Close: Feb 20, 2026
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized ma
Mechelen, Belgium and Philadelphia, PA, U.S. and Oxford, UK; 30 May 2024 22:01 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) and Adaptimmune Therapeutics
Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript
10:07am, Wednesday, 15'th May 2024
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2024 Earnings Conference Call May 15, 2024 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Ga
Adaptimmune Reports Q1 2024 Financial and Business Updates
07:30am, Wednesday, 15'th May 2024
Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date of August 4th, 2024 Commercial and manufacturing in
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
07:00am, Wednesday, 15'th May 2024
First tranche of $25 million available upon closing; the Company will be eligible to draw an additional $25 million subject to afami-cel approval Philadelphia, Pennsylvania and Oxford, United Kindgom-
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
12:00pm, Wednesday, 01'st May 2024
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell
Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
11:00am, Friday, 26'th Apr 2024
Adaptimmune is presenting at ASCO, potentially providing updates on their drug development projects. Their pipeline includes Afami-cel, which has shown promising results in solid tumors, and Lete-cel,
Adaptimmune (ADAP) Down on End of Collaboration With Roche
03:16pm, Monday, 15'th Apr 2024
Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise Update on afami-cel launch plans to be provided at the April
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
07:30pm, Wednesday, 27'th Mar 2024
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with c
Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript
09:29am, Wednesday, 06'th Mar 2024
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q4 2023 Earnings Conference Call March 6, 2024 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer G
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
07:00am, Wednesday, 06'th Mar 2024
U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date of August 4th, 2024 Confirmatory evidence for afami-cel full approval agreed wi
Cintia Piccina returns as Chief Commercial Officer effective March 18, 2024 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
04:00pm, Wednesday, 21'st Feb 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers wit
If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade Philadelphia, Pennsylvania and O
